326 related articles for article (PubMed ID: 18572225)
1. Frequent inactivation of RUNX3 in endometrial carcinoma.
Yoshizaki T; Enomoto T; Fujita M; Ueda Y; Miyatake T; Fujiwara K; Miyake T; Kimura T; Yoshino K; Kimura T
Gynecol Oncol; 2008 Sep; 110(3):439-44. PubMed ID: 18572225
[TBL] [Abstract][Full Text] [Related]
2. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
Jiang Y; Tong D; Lou G; Zhang Y; Geng J
Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
[TBL] [Abstract][Full Text] [Related]
3. Frequent hemizygous deletion at 1p36 and hypermethylation downregulate RUNX3 expression in human lung cancer cell lines.
Yanada M; Yaoi T; Shimada J; Sakakura C; Nishimura M; Ito K; Terauchi K; Nishiyama K; Itoh K; Fushiki S
Oncol Rep; 2005 Oct; 14(4):817-22. PubMed ID: 16142337
[TBL] [Abstract][Full Text] [Related]
4. Decreased expression and frequent allelic inactivation of the RUNX3 gene at 1p36 in human hepatocellular carcinoma.
Mori T; Nomoto S; Koshikawa K; Fujii T; Sakai M; Nishikawa Y; Inoue S; Takeda S; Kaneko T; Nakao A
Liver Int; 2005 Apr; 25(2):380-8. PubMed ID: 15780064
[TBL] [Abstract][Full Text] [Related]
5. Progesterone receptor B gene inactivation and CpG hypermethylation in human uterine endometrial cancer.
Sasaki M; Dharia A; Oh BR; Tanaka Y; Fujimoto S; Dahiya R
Cancer Res; 2001 Jan; 61(1):97-102. PubMed ID: 11196205
[TBL] [Abstract][Full Text] [Related]
6. Promoter hypermethylation of the RUNX3 gene in esophageal squamous cell carcinoma.
Long C; Yin B; Lu Q; Zhou X; Hu J; Yang Y; Yu F; Yuan Y
Cancer Invest; 2007 Dec; 25(8):685-90. PubMed ID: 18058463
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic inactivation of the RUNX3 gene in lung cancer.
Sato K; Tomizawa Y; Iijima H; Saito R; Ishizuka T; Nakajima T; Mori M
Oncol Rep; 2006 Jan; 15(1):129-35. PubMed ID: 16328045
[TBL] [Abstract][Full Text] [Related]
8. RUNX3 protein is overexpressed in human epithelial ovarian cancer.
Nevadunsky NS; Barbieri JS; Kwong J; Merritt MA; Welch WR; Berkowitz RS; Mok SC
Gynecol Oncol; 2009 Feb; 112(2):325-30. PubMed ID: 18937968
[TBL] [Abstract][Full Text] [Related]
9. Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines.
Ku JL; Kang SB; Shin YK; Kang HC; Hong SH; Kim IJ; Shin JH; Han IO; Park JG
Oncogene; 2004 Sep; 23(40):6736-42. PubMed ID: 15273736
[TBL] [Abstract][Full Text] [Related]
10. Frequent loss of RUNX3 expression by promoter hypermethylation in gastric carcinoma.
Oshimo Y; Oue N; Mitani Y; Nakayama H; Kitadai Y; Yoshida K; Ito Y; Chayama K; Yasui W
Pathobiology; 2004; 71(3):137-43. PubMed ID: 15051926
[TBL] [Abstract][Full Text] [Related]
11. Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines.
Wada M; Yazumi S; Takaishi S; Hasegawa K; Sawada M; Tanaka H; Ida H; Sakakura C; Ito K; Ito Y; Chiba T
Oncogene; 2004 Mar; 23(13):2401-7. PubMed ID: 14743205
[TBL] [Abstract][Full Text] [Related]
12. Decreased expression of RUNX3 is correlated with tumor progression and poor prognosis in patients with esophageal squamous cell carcinoma.
Sugiura H; Ishiguro H; Kuwabara Y; Kimura M; Mitsui A; Mori Y; Ogawa R; Katada T; Harata K; Fujii Y
Oncol Rep; 2008 Mar; 19(3):713-9. PubMed ID: 18288406
[TBL] [Abstract][Full Text] [Related]
13. DCC genetic alterations and expression in endometrial carcinoma.
Ronnett BM; Burks RT; Cho KR; Hedrick L
Mod Pathol; 1997 Jan; 10(1):38-46. PubMed ID: 9021725
[TBL] [Abstract][Full Text] [Related]
14. RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors.
Kim WJ; Kim EJ; Jeong P; Quan C; Kim J; Li QL; Yang JO; Ito Y; Bae SC
Cancer Res; 2005 Oct; 65(20):9347-54. PubMed ID: 16230397
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of SPARC protein contrasts with its transcriptional silencing by aberrant hypermethylation of SPARC CpG-rich region in endometrial carcinoma.
Rodríguez-Jiménez FJ; Caldés T; Iniesta P; Vidart JA; Garcia-Asenjo JL; Benito M
Oncol Rep; 2007 Jun; 17(6):1301-7. PubMed ID: 17487382
[TBL] [Abstract][Full Text] [Related]
16. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression.
Subramaniam MM; Chan JY; Soong R; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
Breast Cancer Res Treat; 2009 Jan; 113(1):113-21. PubMed ID: 18256927
[TBL] [Abstract][Full Text] [Related]
17. Multiple promoters of catechol-O-methyltransferase gene are selectively inactivated by CpG hypermethylation in endometrial cancer.
Sasaki M; Kaneuchi M; Sakuragi N; Dahiya R
Cancer Res; 2003 Jun; 63(12):3101-6. PubMed ID: 12810635
[TBL] [Abstract][Full Text] [Related]
18. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor.
Kim EJ; Kim YJ; Jeong P; Ha YS; Bae SC; Kim WJ
J Urol; 2008 Sep; 180(3):1141-5. PubMed ID: 18639281
[TBL] [Abstract][Full Text] [Related]
19. Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers.
Xiong Y; Dowdy SC; Xue A; Shujuan J; Eberhardt NL; Podratz KC; Jiang SW
Gynecol Oncol; 2005 Mar; 96(3):601-9. PubMed ID: 15721400
[TBL] [Abstract][Full Text] [Related]
20. Possible involvement of RUNX3 silencing in the peritoneal metastases of gastric cancers.
Sakakura C; Hasegawa K; Miyagawa K; Nakashima S; Yoshikawa T; Kin S; Nakase Y; Yazumi S; Yamagishi H; Okanoue T; Chiba T; Hagiwara A
Clin Cancer Res; 2005 Sep; 11(18):6479-88. PubMed ID: 16166423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
